Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more
Theranexus SA (ALTHX) - Total Assets
Latest total assets as of June 2025: €4.53 Million EUR
Based on the latest financial reports, Theranexus SA (ALTHX) holds total assets worth €4.53 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theranexus SA - Total Assets Trend (2015–2024)
This chart illustrates how Theranexus SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Theranexus SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Theranexus SA's total assets of €4.53 Million consist of 69.0% current assets and 31.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €252.28K | 19.1% |
| Accounts Receivable | €582.07K | 15.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €3.47K | 0.1% |
| Intangible Assets | €1.00 Million | 26.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Theranexus SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theranexus SA's current assets represent 69.0% of total assets in 2024, a decrease from 92.1% in 2015.
- Cash Position: Cash and equivalents constituted 19.1% of total assets in 2024, up from 2.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 7.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 26.8% of total assets.
Theranexus SA Competitors by Total Assets
Key competitors of Theranexus SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Theranexus SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Theranexus SA generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Theranexus SA is currently not profitable relative to its asset base.
Theranexus SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 1.21 | 3.16 |
| Quick Ratio | 0.86 | 1.67 | 3.16 |
| Cash Ratio | 0.39 | 0.53 | 0.00 |
| Working Capital | €-539.56K | € 533.11K | € 8.42 Million |
Theranexus SA - Advanced Valuation Insights
This section examines the relationship between Theranexus SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 7.35 |
| Asset Growth Rate (YoY) | -48.3% |
| Total Assets | €3.74 Million |
| Market Capitalization | $27.49 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theranexus SA's assets at a significant premium ( 7.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Theranexus SA's assets decreased by 48.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theranexus SA (2015–2024)
The table below shows the annual total assets of Theranexus SA from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €3.74 Million | -48.33% |
| 2023-12-31 | €7.24 Million | -39.95% |
| 2022-12-31 | €12.05 Million | -28.63% |
| 2021-12-31 | €16.89 Million | -3.32% |
| 2020-12-31 | €17.47 Million | +13.67% |
| 2019-12-31 | €15.37 Million | -18.46% |
| 2018-12-31 | €18.85 Million | -7.49% |
| 2017-12-31 | €20.38 Million | +607.31% |
| 2016-12-31 | €2.88 Million | +5.67% |
| 2015-12-31 | €2.73 Million | -- |